morita tatsuo

FacultyUrology
Job titleProfessorWeb site

Profile

Research Keywords

    Urogenital Cancer

Research Areas

  • Clinical surgery / Urology

Career

  • Jichi Medical University, Professor

Research Activities

Papers(other)

  • In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
    J. Natl. Cancer Inst. 78 1987
  • Intra-arterial infusion chemotherapy with [Sar1, Ile8] angiotensin II for bladder cancer.
    Am. J. Clin. Oncol. 15(3) 1992
  • Analysis of NK activity and NK cell subseuts in bladder cancer patients.
    Cancer Immunol, Immunother. 32 1990
  • Evaluation of lymphocyte subpopulations in patients with bladder cancer : a study with monoclonal antibodies.
    Acta Urol. Jpn. 33(6) 1987
  • T cell functions of IL-2-activated Tumor-infiltrating Lymphocytes from renal cell carcinoma
    Reg. Immunol 4,225-235 1992
  • Oligoclonal expansion of Vβ8+ cells in interleukin-2-activated T cells residing in subcutaneous metastatic melanoma
    Clin. Exp. Metastasis 10,69-76 1992
  • Clinical significance of serum S100ao protein in patients with renal cell carcinoma
    Diagnostic Oncology 2 277 1992
  • Antitumor effect of a synthetic analogue of fumagillin on murine renal carcinoma
    British Journal of Urology 74 416 1994
  • Squamous cell caruinoma of the ureter with marked leukocytosis producing granulocyte colong-stimulating factor
    Urol. Int. 55 32-33 1995
  • Establishment and characterization of a new cell line from human bladder cancer(JMSU1)
    Urol. Res. 23 143-149 1995
Display all
Papers(other)close
  • In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
    J. Natl. Cancer Inst. 78 1987
  • Intra-arterial infusion chemotherapy with [Sar1, Ile8] angiotensin II for bladder cancer.
    Am. J. Clin. Oncol. 15(3) 1992
  • Analysis of NK activity and NK cell subseuts in bladder cancer patients.
    Cancer Immunol, Immunother. 32 1990
  • Evaluation of lymphocyte subpopulations in patients with bladder cancer : a study with monoclonal antibodies.
    Acta Urol. Jpn. 33(6) 1987
  • T cell functions of IL-2-activated Tumor-infiltrating Lymphocytes from renal cell carcinoma
    Reg. Immunol 4,225-235 1992
  • Oligoclonal expansion of Vβ8+ cells in interleukin-2-activated T cells residing in subcutaneous metastatic melanoma
    Clin. Exp. Metastasis 10,69-76 1992
  • Clinical significance of serum S100ao protein in patients with renal cell carcinoma
    Diagnostic Oncology 2 277 1992
  • Antitumor effect of a synthetic analogue of fumagillin on murine renal carcinoma
    British Journal of Urology 74 416 1994
  • Squamous cell caruinoma of the ureter with marked leukocytosis producing granulocyte colong-stimulating factor
    Urol. Int. 55 32-33 1995
  • Establishment and characterization of a new cell line from human bladder cancer(JMSU1)
    Urol. Res. 23 143-149 1995
  • Association of renal cell carcinoma and angiomyo lipsma in the same kidney
    Urologia Internationalis 43 297 1988
  • Primary malignant melanoma of male urethra with fistuld formation
    Urologia Internationalis 46 114 1991
  • Cytokeratin 19 Fragment(CYFRA 21-1)in Bladder Cancer
    European Urology 32 237 1997
  • Successful closure of neovesicocutaneous fistula with fibrin glue
    (]E87CD[)rol.Int. 61 130-131 1998
  • BiomodulaTion of 5-fluorouracil by interferon x in human renal carcinomd cells : Relation to the expression of thy midine phosphorylase.
    Cancer Chem Pharm 44(2) 91-96 1999
  • Successful endoscopic closure of radiation-induced vesicovaginal fistula with fibrin glue and bovine collagen
    J.(]E87CD[)rot. 162 1689 1999
  • Serum anti-p53 antibodies and p53 protein status in the serd and tumors from bladder cancer patients
    Eur.(]E87CD[)rol. 37 79-84 2000
  • Patent Urachus
    New Eng.J.Med. 343(1) 36 2000
  • Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    International Journal of Cancer 92(3) 451-456 2001
  • Role of thymidine phosphorylase in biomodulation of fluoropyrimidines.
    Current Pharmaceutical Biotechnology 2 257-267 2001

Outside Fund Adoption

  • Biological Heterogeneity of Bladder Cancer
Display all
Outside Fund Adoptionclose
  • Biological Heterogeneity of Bladder Cancer


Copyright c MEDIA FUSION Co.,Ltd. All rights reserved.